Treatment of Gram-positive surgical sepsis: Role of the oxazolidinones

Journal of Chemotherapy

Volumn 15, Issue 4, 2003, Pages 323-328

  Colizza, S ^a   Rossi, S ^b   Rodio, F ^b   Carnuccio, P ^c   Cucchiara, G ^a  

^a Fatebenefratelli Isola Tiberina ^*  (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antibiotic resistance; Gram positive sepsis; Linezolid; Oxazolidinones; Surgical sepsis

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; LINEZOLID; MACROLIDE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; HEADACHE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INSOMNIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; REVIEW; SEPSIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VOMITING;

EID: 0042347851     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.4.323     Document Type: Review

References (42)

1. Centers for Disease Controls and Prevention, National Center for Health Statistics. Mortality patterns-United States 1990. Monthly Vital Stat Rep 1993; 41: 45.
2. Moro ML, Stazi MA, Marasca G et al. National prevalence survey of hospital-aquired infections in Italy, 1983. J Hosp Infect 1986; 8(1): 72-85.
3. Haley RW, Culver DH, White JW et al. The nationwide nosocomial infection rate. A new need for vital statistics. Am J Epidemiol 1985; 121(2): 159-167.
4. Wenzel RP. Preoperative antibiotic prophylaxis. N Engl J Med 1991; 326: 337.
5. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. Centre for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Contr 1999; 27: 97-132.
6. Garner JS, Jarvis WR, Emory TG et al. CDC definitions for nosocomial infections, 1988. Ann Infect Contr 1988;16:128-140.
7. Colizza S, Rossi S. Razionale della profilassi antibiotica in chirurgia. Arch Atti Soc It Chir 2000; 1: 249-298.
8. Nichols RL. Surgical infections: prevention and treatment -1965 to 1995. Am J Surg 1996; 172: 68-74.
9. Meakins JL, Solomkin JS, Allo MD et al. A proposed classification of intra-abdominal infections: stratification of etiology and risk for future therapeutic trials. Arch Surg 1984; 119: 1372-1378.
10. Montravers P, Pepers S, Popesco D. Prise en charge post-operatoire. Reanimation des sepsis intra-abdominaux apres intervention chirurgicale. Presse Med 1999; 28: 198-202.
11. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 (suppl A): 19-24.
12. Banerijee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 865-895.
13. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care unit in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study.!JAMA 1995; 274: 639-644.
14. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
15. Diekema DJ, Pfaller MA, Schmitz FJ et al. and the SENTRY Participants Group. Survey of infections due to Staphylococcus sp: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32: S114-132.
16. Ginzburg E, Namias N, Brown M et al. Gram positive infections in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity. Int J Antimicrob Agents 2000; 16: S39-S42.
17. Diekema DJ, Jones RN. Oxazilidinone antibiotics. Lancet 2001; 358: 1975-1982.
18. Doern GV, Jones RN, Pfaller MA et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada). Diagn Microbiol Infect Dis 1999; 34: 65-72.
19. Colizza S, Rossi S. Antibiotic prophylaxis and treatment of surgical abdominal sepsis. J Chemother 2001; 13: 193-201.
20. Gold HS, Moellering RC Jr. Antimicrobial drug resistance. N Engl J Med 1996; 335: 1445-1453.
21. Corti G, Cinelli R, Paradisi F. Clinical and microbiological efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int J Antimicrob Agents 2000; 16: 527-530.
22. Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother 1995 (suppl):1-23
23. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 4-7, 1987, Abstract 244, p 139.
24. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
25. French G. Linezolid. Int J Clin Pract 2001; 55: 59-63.
26. French G. Linezolid. Int J Clin Pract 2001; 55: 59-63.
27. Perry CM, Jarvis B. Linezolid. A review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525-551.
28. Green SL, Maddox JC, Huttenbach Ed. Linezolid and reversible myelosuppression. (Letter). JAMA 2001; 285: 1291.
29. Burnett RJ, Haverstock DC, Dellinger EP et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomised trial. Surgery 1995; 118: 716-721.
30. Schulin T, Thauvin-Eliopolos C, Moellering RC Jr et al. Activities of the oxazolidinones linezolid and eperozolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 2873-2876.
31. th International Congress of Infectious Diseases Buenos Aires). Boston: International Society of Infectious Diseases, 2000.
32. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-3413.
33. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146-151.
34. Antony SJ, Diaz-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant gram-positive infections. J Natl Med Assoc 2001; 93: 386-391.
35. Presterl EC, Apfalter P, Rath T et al. Long term treatment with linezolid in a patient with mediastinitis caused by small variant MSRA. Int J Antimicrob Agents 2002; 19 (suppl. 1) S19.
36. Colizza S, Rossi S. Il trattamento delle sepsi chirurgiche primarie e secondarie. Arch Atti Soc It Chir 2001; 2: 401-413.
37. Bailey EM, Faber MD, Nafzinger DA. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis 2001; 38: E20.
38. Wilcox M, Tang T, Hafkin B. Linezolid versus teicoplanin for the treatment of hospitalised patients with gram-positive infections. Poster 1481 - 41° ICAAC - December 2001.
39. Li Z, Willke RJ, Pinto LA et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomised, multicenter trial. Pharmacotherapy 2001; 21: 263-274.
40. Linezolid (Zyvox). Med Lett Drug Ther 2000; 42: 45-6.
41. th European Congress of Chemotherapy and Infection, Paris 4-7 May 2002).
42. th European Congress of Chemotherapy and Infection, Paris 4-7 May 2002).